149 related articles for article (PubMed ID: 21087604)
1. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H
Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604
[TBL] [Abstract][Full Text] [Related]
2. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity.
Goldoni S; Iozzo RA; Kay P; Campbell S; McQuillan A; Agnew C; Zhu JX; Keene DR; Reed CC; Iozzo RV
Oncogene; 2007 Jan; 26(3):368-81. PubMed ID: 16847455
[TBL] [Abstract][Full Text] [Related]
3. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
[TBL] [Abstract][Full Text] [Related]
4. LRIG1 expression in colorectal cancer.
Ljuslinder I; Golovleva I; Palmqvist R; Oberg A; Stenling R; Jonsson Y; Hedman H; Henriksson R; Malmer B
Acta Oncol; 2007; 46(8):1118-22. PubMed ID: 17851870
[TBL] [Abstract][Full Text] [Related]
5. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.
Guo D; Nilsson J; Haapasalo H; Raheem O; Bergenheim T; Hedman H; Henriksson R
Acta Neuropathol; 2006 Mar; 111(3):238-46. PubMed ID: 16532360
[TBL] [Abstract][Full Text] [Related]
6. LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway.
Li F; Yang W; Guo D; Hu Z; Xu H; Ye Z
Oncol Rep; 2011 Jun; 25(6):1629-37. PubMed ID: 21431282
[TBL] [Abstract][Full Text] [Related]
7. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
Sanderson MP; Dempsey PJ; Dunbar AJ
Growth Factors; 2006 Jun; 24(2):121-36. PubMed ID: 16801132
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
9. Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.
Li F; Ye ZQ; Guo DS; Yang WM
Oncol Rep; 2011 Aug; 26(2):439-46. PubMed ID: 21567105
[TBL] [Abstract][Full Text] [Related]
10. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N
Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953
[TBL] [Abstract][Full Text] [Related]
11. Characterization and tissue-specific expression of human LRIG2.
Holmlund C; Nilsson J; Guo D; Starefeldt A; Golovleva I; Henriksson R; Hedman H
Gene; 2004 May; 332():35-43. PubMed ID: 15145052
[TBL] [Abstract][Full Text] [Related]
12. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.
Sartor CI; Dziubinski ML; Yu CL; Jove R; Ethier SP
Cancer Res; 1997 Mar; 57(5):978-87. PubMed ID: 9041204
[TBL] [Abstract][Full Text] [Related]
13. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
Ahmad N; Gali H; Javed S; Agarwal R
Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
[TBL] [Abstract][Full Text] [Related]
14. Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation.
Li M; Wang J; Ng SS; Chan CY; He ML; Yu F; Lai L; Shi C; Chen Y; Yew DT; Kung HF; Lin MC
Cancer; 2009 Nov; 115(21):4959-72. PubMed ID: 19642173
[TBL] [Abstract][Full Text] [Related]
15. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
16. Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells.
Ding W; Shi W; Bellusci S; Groffen J; Heisterkamp N; Minoo P; Warburton D
J Cell Physiol; 2007 Sep; 212(3):796-806. PubMed ID: 17516543
[TBL] [Abstract][Full Text] [Related]
17. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
18. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence.
Jensen KB; Watt FM
Proc Natl Acad Sci U S A; 2006 Aug; 103(32):11958-63. PubMed ID: 16877544
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of signal regulatory protein alpha1 inhibitory receptors by epidermal growth factor receptor signaling.
Kapoor GS; Kapitonov D; O'Rourke DM
Cancer Res; 2004 Sep; 64(18):6444-52. PubMed ID: 15374953
[TBL] [Abstract][Full Text] [Related]
20. Aryl Hydrocarbon Receptor Defect Attenuates Mitogen-Activated Signaling through Leucine-Rich Repeats and Immunoglobulin-like Domains 1 (LRIG1)-Dependent EGFR Degradation.
Hsu HL; Chen HK; Tsai CH; Liao PL; Chan YJ; Lee YC; Lee CC; Li CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
